Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dare Bioscience, Inc. Director's Dealing 2017

Jan 9, 2017

34825_dirs_2017-01-09_948e2c95-afa0-4c5c-ae75-5c23b1054ce9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2017-01-05

Reporting Person: BELOFF GREGG (CFO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-01-05 Stock Option (right to buy) $0.82 A 50000 Acquired 2027-01-04 Common Stock (50000) Direct

Footnotes

F1: This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.